curcumin/Finding

One finding, on its own

A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.

Decreases aspartate aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×6
“Similarly, the mean AST reduction was − 15.03 ± 16.31 U/L in the nanocurcumin group and − 0.92 ± 11.64 U/L in the placebo group, with a significant between-group difference ( P = 0.004).”
Quoted verbatim from Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial..
Study

RCT
Dose

Oral nanomicellar curcumin (nano-curcumin, Exir Nano Sina), one 40 mg capsule twice daily with a main meal (80 mg/day) for 16 weeks
Population

Adults aged 30-70 y with NAFLD-associated liver fibrosis of METAVIR stage F2 or higher, Tehran, Iran; 55 randomised and all 55 analysed with no withdrawals (27 nano-curcumin, 28 placebo); secondary endpoint (declared primary outcomes: liver fibrosis and steatosis by FibroScan and the FIB-4 index); unadjusted between-group comparison of change from baseline; baseline AST was higher in the nano-curcumin arm than in the placebo arm (38.44 vs 27.21 U/L, P = 0.05); serum AST by enzyme colorimetric method on a Cobas c 311 analyser
Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial.2025PMID:41168313Industry fundedPermalink

Keep reading

To cite this finding: https://catalystproject.ai/e/01M0Q4SY8QPKMTTRE4FGAME92V

curcumin/Finding

One finding, on its own

A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.

Decreases aspartate aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×6
“Similarly, the mean AST reduction was − 15.03 ± 16.31 U/L in the nanocurcumin group and − 0.92 ± 11.64 U/L in the placebo group, with a significant between-group difference ( P = 0.004).”
Quoted verbatim from Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial..
Study

RCT
Dose

Oral nanomicellar curcumin (nano-curcumin, Exir Nano Sina), one 40 mg capsule twice daily with a main meal (80 mg/day) for 16 weeks
Population

Adults aged 30-70 y with NAFLD-associated liver fibrosis of METAVIR stage F2 or higher, Tehran, Iran; 55 randomised and all 55 analysed with no withdrawals (27 nano-curcumin, 28 placebo); secondary endpoint (declared primary outcomes: liver fibrosis and steatosis by FibroScan and the FIB-4 index); unadjusted between-group comparison of change from baseline; baseline AST was higher in the nano-curcumin arm than in the placebo arm (38.44 vs 27.21 U/L, P = 0.05); serum AST by enzyme colorimetric method on a Cobas c 311 analyser
Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial.2025PMID:41168313Industry fundedPermalink

Keep reading

To cite this finding: https://catalystproject.ai/e/01M0Q4SY8QPKMTTRE4FGAME92V